A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.
Fiona Simpkins
No relevant relationships to disclose
Aurea M. Flores
No relevant relationships to disclose
Christina Chu
No relevant relationships to disclose
Joseph A. Lucci
No relevant relationships to disclose
Jonathan S. Berek
No relevant relationships to disclose
George Coukos
No relevant relationships to disclose
John W. Bauman
Stock Ownership - GlaxoSmithKline
Sharon Cornell Murray
Stock Ownership - GlaxoSmithKline
Herbert Struemper
Stock Ownership - GlaxoSmithKline
Fiona Germaschewski
Stock Ownership - GlaxoSmithKline
Zdenka Jonak
No relevant relationships to disclose
Olivia S. Gardner
Stock Ownership - GlaxoSmithKline
John F Toso
Stock Ownership - GlaxoSmithKline